2,395 results
P
I/C
l, o, w, -, l, e, v, e, l, , a, r, s, e, n, i, c, , (, A, s, ), , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r, d, r, i, n, k, i, n, g, , w, a, t, e, r, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, s, , l, o, w, e, r, , t, h, a, n, , t, h, e, , W, H, O, , p, r, o, v, i, s, i, o, n, a, l, , g, u, i, d, e, l, i, n, e, , v, a, l, u, e, , (, 1, 0, , µ, g, /, L, )
O
p, o, o, l, e, d, , a, s, s, o, c, i, a, t, i, o, n, , b, e, t, w, e, e, n, , t, h, e, , r, e, l, a, t, i, v, e, , r, i, s, k, , o, f, , e, a, c, h, , c, a, r, d, i, o, v, a, s, c, u, l, a, r, , d, i, s, e, a, s, e, , (, C, V, D, ), , e, n, d, p, o, i, n, t, , a, n, d, , l, o, w, -, l, e, v, e, l, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r
P
Oral anticoagulants (OAC), P-glycoprotein (P-gp)/CYP3A4 enzyme
I/C
P-gp/CYP3A4 inhibitors, Rivaroxaban, Dabigatran, Apixaban, Edoxaban, Warfarin
O
Major bleeding, Gastrointestinal (GI) bleeding, Stroke/systemic embolism (SE), All-cause mortality, Any bleeding, Intracranial hemorrhage (ICH)
P
COVID-19 survivors (S), nonsurvivors (NS)
I/C
echocardiographic systolic pulmonary arterial pressure (sPAP) measurement, sPAP difference between nonsurvivors and survivors
O
11.8mmHg (95% CI, 6.60-16.97; P < 0.0001, I2 = 89.3%) higher in NS compared with S
P
metastatic or recurrent gastric cancer patients
I/C
capecitabine-based chemotherapy, S-1-based chemotherapy
O
objective response rate, 6-, 12-, and 18-month progression-free survival, 1-, 2-, and 3-year overall survival, adverse events (hand-foot syndrome, neutropenia)
P
soil microbial extracellular hydrolytic enzymatic activities (Hy-EEAs), soil oxidative enzymatic activities (Ox-EEAs), soil carbon (C), soil nitrogen (N), soil phosphorus (P)
I/C
natural forest conversion (NFC), Changes in soil Hy- and Ox-EEAs, changes in soil organic C, available P, microbial biomass C and N
O
depletion of soil organic carbon, stimulated soil microbial secretion of Hy- and Ox-EEAs, soil total N scarcity, provoke soil microbial Hy-EEAs, soil total P dearth, quickened the soil Ox-EEAs, plenitude of soil available P, suppressed soil Hy- and Ox-EEAs
P
hypercholesterolemia adults
I/C
combination therapy with ezetimibe and statins (E/S), double dose of statin (D/S) monotherapy, ezetimibe and statins vs. double dose of statin
O
low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), high-density lipoprotein (HDL)
P
patients with an indication for ICD without the need for pacing
I/C
S-ICD, TV-ICD
O
composite of clinically relevant device-related complications and inappropriate shock
P
patients with coronary artery disease (CAD)
I/C
robotically assisted PCI (R-PCI), standard PCI (S-PCI)
O
clinical success, procedure time, fluoroscopy time, contrast use, radiation exposure
P
GSNO
I/C
S-Nitrosoglutathione, Placebo
O
Infarct size, Neurological behavior scales, Embolic signals
P
BPTB autograft group, 4S-HT autograft group
I/C
ACLR with BPTB autograft, ACLR with 4S-HT autograft, BPTB autograft vs. 4S-HT autograft
O
knee anteroposterior and rotational stability, side-to-side difference on knee laxity, pivot-shift test, IKDC objective grade, donor-site related complications, short-term iskinetic peak flexion torques at 60°/S and 240°/S, mid- to long-term knee functional outcomes